

DAFTAR PUSTAKA

Adams *et al.*, 2014. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. *J Clin Oncol.* 2014;32(27):2959–2966.

Al Farisyi *et al.*, 2018. Al Farisyi M, Khambri D. Analisis Survival Pasien Kanker Payudara Usia Muda di RSUP DR. M. Djamil Padang Tahun 2008- 2017. *J Kesehat Andalas.* 2018;7(Supplement 4):25

Al-Mutairi *et al.*, 2022. Al-Mutairi M.S., Habashy H.O. Nuclear Factor-κB Clinical Significance in Breast Cancer: An Immunohistochemical Study. *Med Princ Pract.* DOI: 10.1159/000527828

American Cancer Society, 2021. *Cancer Facts & Figures 2021.* Atlanta: American Cancer Society; 2021.

Andrade *et al.*, 2017. Andrade SS, Sumikawa JT, Castro ED, Batista FP, Paredes-Gamero E, Oliveira LC, *et al.* Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells. *Oncotarget.* 2017 Mar 7;8(10):16851–74. <https://doi.org/10.18632/oncotarget.15170>

Anwar *et al.*, 2020. Anwar SL, Avanti WS, Nugroho AC, Choridah L, Dwianingsih EK, Harahap WA, et al. Risk factors of distant metastasis after surgery among different breast cancer subtypes: A hospital-based study in Indonesia. *World J Surg Oncol.* 2020;18(1):1–16.

Ardhiansyah AO. 2021. *Surgery Mapping Bedah Onkologi. Dasar-Dasar Onkologi dan Hallmark Of Cancer Dari Teori Preklinik Hingga Aplikasi Klinik*, Edisi 2. Surabaya: Airlangga University Press.

Ardiansyah, 2021. *Kanker Payudara dari Teori Preklinik Hingga Aplikasi Klinik*, Surabaya: Airlangga University Press.

Asano *et al.*, 2016. Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, *et al.* Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer. *PloS One* (2016) 11(7): e0153459. doi: 10.1371/journal.pone.0153459

Battinelli *et al.*, 2011. Battinelli EM, Markens BA, Italiano JE. Release of angiogenesis regulatory proteins from platelet *alpha* granules: modulation of physiologic and pathologic angiogenesis. *Blood*. 2011 Aug 4;118(5): 1359–69. <https://doi.org/10.1182/blood-2011-02-334524>

Best *et al.*, 2018. Best MG, Wesseling P, Wurdinger T. Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring. *Cancer Res*. 2018 Jun 19;canres;0008-5472.CAN-18-0887v1. <https://doi.org/10.1158/0008-5472.CAN-18-0887>

Brown *et al.*, 2008. Brown M, Cohen J, Arun P, *et al.* NF- κ B in Carcinoma Therapy and Prevention. *Expert Opin Ther Targets*. 2008 September ; 12(9): 1109–1122. doi:10.1517/14728222.12.9.1109.

Chang *et al.*, 2011. Chang MC, Jeng JH. Tumor Cell-Induced Platelet Aggregation. In: Schwab M, editor. *Encyclopedia of Cancer* [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2011 [cited 2022 May 18]. p. 3793–5. Available from: http://link.springer.com/10.1007/978-3-642-16483-5_6023 https://doi.org/10.1007/978-3-642-16483-5_6023

Chlebowski *et al.*, 2013. Chlebowski RT, Manson JE, *et al.* Estrogen plus progestin and breast cancer incidence and mortality in the Women’s Health Initiative Observational Study. *J Natl Cancer Inst*. 2013 Apr 17;105(8):146-51

Cho *et al.*, 2018. Cho U, Park HS, Im SY, Yoo CY, Jung JH, Suh YJ, *et al.* Prognostic Value of Systemic Inflammatory Markers and Development of a Nomogram in Breast Cancer. *PloS One* (2018) 13(7):e0200936. doi: 10.1371/journal.pone.0200936

Collignon *et al.*, 2016. Collignon J, Lousberg L, Schroeder H, *et al.* Triple-negative breast cancer: treatment challenges and solutions. *Breast Cancer: Targets and Therapy* 2016;8 93–107

Costa *et al.*, 2018. Costa R, Hansen N, Gradishar WJ. Locally Advanced Breast Cancer. In the breast: Comprehensive management of benign and malignant disease. Elsevier. 2018;6:819-831. <https://doi.org/10.1016/B978-0-323-35955-9.00063-5>.

Devanaboyina M, Kaur J, et al (2022) NF- κ B Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer. *Oncol. Rev.* 16:10568. doi: 10.3389/or.2022.10568

Dhanushkodi *et al.*, 2021. Dhanushkodi M, Sridevi V, Shanta V, et al. Locally Advanced Breast Cancer (LABC): Real-World Outcome of Patients From Cancer Institute, Chennai. *JCO Global Oncology* (2021) 7:767-781. *American Society of Clinical Oncology*

Dominska *et al.*, 2017. Dominska K, Kowalska K, *et al.* Regulation of mRNA gene expression of members of the NF- κ B transcription factor gene family by angiotensin II and relaxin 2 in normal and cancer prostate cell lines. *Molecular Medicine Reports* 15: 4352-4359, 2017

Fasoulakis *et al.*, 2019. Fasoulakis Z, Daskalakis G, Diakosavvas M, Papapanagiotou I, Theodora M, Bourazan A, et al. MicroRNAs Determining Carcinogenesis by Regulating Oncogenes and Tumor Suppressor Genes During Cell Cycle. *MicroRNA*. 2019;9(2):82–92.

Geyer, Felipe C., et al. "The spectrum of triple-negative breast disease: high- and low-grade lesions." *The American journal of pathology* 187.10 (2017): 2139-2151.

Giordano *et al.*, 2003. Giordano SH. Update on Locally Advanced Breast Cancer. *The Oncologist*. 2003;8(6):521-530. doi:10.1634/theoncologist.8-6-521\

Goldhirsch, A., Winer, EP., Coates, AS., Gelber, RD., Pichart-Gebhart, M., Thurlimann, B. *et al.*, 2013, Personalizing the treatment of women with early breast

cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, *Annals of Oncology*, 2206-2223.

Gorelik *et al*, 2002. Gorelik L, Flavell RA. Transforming growth factor- β in T-cell biology. *Nat Rev Immunol*. 2002 Jan;2(1):46–53. <https://doi.org/10.1038/nri704>

Graziano *et al.*, 2018. Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, Barba M, et al. Combination of Peripheral Neutrophil-to-Lymphocyte Ratio and Platelet to-Lymphocyte Ratio Is Predictive of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Patients. *Breast Edinb Scotl* (2019) 44:33–8. doi: 10.1016/j.breast.2018.12.014

Han *et al*, 2014. Han H, Cao FL, Wang BZ, Mu XR, Li GY, Wang XW. Expression of Angiogenesis Regulatory Proteins and Epithelial-Mesenchymal Transition Factors in Platelets of the Breast Cancer Patients. *Sci World J*. 2014;2014:1–7. <https://doi.org/10.1155/2014/878209>

Halperin, Edward C., et al. Perez & Brady's principles and practice of radiation oncology. Lippincott Williams & Wilkins, 2013.

Hanahan D *et al*. 2022. Hallmarks of Cancer: New Dimensions. *Cancer Discov* 1 January; 12 (1): 31–46.

Hanahan *et al*, 2011. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. *Cell*. 2011 Mar;144(5): 646–74. <https://doi.org/10.1016/j.cell.2011.02.013>

Indra *et al*, 2021. Indra CM, Asadul Islam, *et al*. The relationship between NF κ B, HER2, ER expression and anthracycline -based neoadjuvan chemotherapy response in local advanced stadium breast cancer: A cohort study in Eastern Indonesia. *Annals of Medicine and Surgery*. 62(2021). 102164. <https://doi.org/10.1016/j.amsu.2021.02.010>

Ishikawa *et al*, 2016. Ishikawa S, Miyashita T, Inokuchi M, Hayashi H, Oyama K, Tajima H, *et al*. Platelets surrounding primary tumor cells are related to chemoresistance. *Oncol Rep*. 2016 Aug;36(2):787–94. <https://doi.org/10.3892/or.2016.4898>

Jiang *et al*, 2017. Jiang L, Luan Y, Miao X, Sun C, Li K, Huang Z, *et al*. Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling. *Br J Cancer*. 2017 Aug;117(5):695–703. <https://doi.org/10.1038/bjc.2017.214>

Kementerian Kesehatan RI, 2018. Kementerian Kesehatan RI. Laporan Nasional Riskesdas 2018. 2018

Keputusan Menteri Kesehatan Republik Indonesia, Nomor HK.01.07/Menkes/414/2018 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara.

Khan, M. and Sarkar, D., 2021. The scope of astrocyte elevated gene-1/metadherin (AEG-1/MTDH) in cancer clinicopathology: A review. *Genes*, 12(2), p.308.

Lambe M, Hsieh C, *et al*. Transient increase in the risk of breast cancer after giving birth. *N Engl J Med*. 1994 Jul 7;331(1):5-9

Lehmann *et al*, 2016. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, *et al*. (2016) Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. *PLoS ONE* 11(6): e0157368. doi:10.1371/journal.pone.0157368

Li *et al*, 2010. Li Z, Delaney MK, O'Brien KA, Du X. Signaling During Platelet Adhesion and Activation. *Arterioscler Thromb Vasc Biol*. 2010 Dec; 30 (12) : 2341–9. <https://doi.org/10.1161/ATVBAHA.110.207522>

Li *et al*, 2014. Li R, Ren M, Chen N, Luo M, Deng X, Xia J, *et al*. Presence of intratumoral platelets is associated with tumor vessel structure and metastasis. *BMC Cancer*. 2014 Dec;14(1):167. <https://doi.org/10.1186/1471-2407-14-167>

Li *et al*, 2022. Li Y, Zhang H, *et al*. Recent advances in therapeutic strategies for triple-negative breast cancer. *Journal of Hematology & Oncology* (2022) 15:121 <https://doi.org/10.1186/s13045-022-01341-0>

Li, C., Li, R., Song, H., Wang, D., Feng, T., Yu, X., Zhao, Y., Liu, J., Yu, X., Wang, Y. and Geng, J., 2011. Significance of aeg-1 expression in correlation with vegf,

microvessel density and clinicopathological characteristics in triple-negative breast cancer. *Journal of surgical oncology*, 103(2), pp.184-192.

Liedtke, C., Hess, K. R., Karn, T., Rody, A., Kiesel, L., Hortobagyi, G. N., Pusztai, L., & Gonzalez-Angulo, A. M. (2013). The prognostic impact of age in patients with triple-negative breast cancer. *Breast Cancer Research and Treatment*, 138, 591–599.

Liu *et al.*, 2018. Liu X ling, Ding J, Meng L hua. Oncogene induced senescence: a double edged sword in cancer. *Acta Pharmacologica Sinica*. 2018;39(10):1553–8.

Liubomirski, S. Lerrer, T. Meshel *et al.*, “Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triple-negative breast cancer,” *Frontiers in Immunology*, vol. 10, p. 757, 2019.

Loi *et al.*, 2013. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. *Oncoimmunology*. 2013;2(7):e24720.

Lopez, 2018. Cuello-Lo´pez J, Fidalgo-Zapata A, Lo´pez Agudelo L, Va´ squez-Trespalacios E (2018) Platelet to lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. *PLoS ONE* 13(11): e0207224. <https://doi.org/10.1371/journal.pone.0207224>

Lusho *et al.*, 2021. Lusho S, Durando X, *et al.* Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients. *Front. Oncol.* 11:678315. doi: 10.3389/fonc.2021.678315

Manna *et al.*, 2021. Manna, D.; Sarkar, D. Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance. *Cancers* 2021, 13, 1792. <https://doi.org/10.3390/cancers13081792>

Manuaba *et al.*, 2010. Manuaba TW. Panduan Penatalaksanaan Kanker Payudara. Panduan Penatalaksanaan Kanker Solid. PERABOI. Sagung Seto. 2010; 1:18– 50

Masood *et al.*, 2016. Masood Shahla. Neoadjuvant chemotherapy in breast cancers. *Women’s Health* 2016, Vol. 12(5) 480–491

Mayrovitz, 2022. Mayrovitz, H., 2022. Breast Cancer. Brisbane, Australia: Exon Publications.

McTiernan, 2019. McTiernan A, Friendenreich CM, Katzmarzyk PT, *et al.* Physical Activity in Cancer Prevention and Survival: A systematic Review. Med Sci Sports Exerc. 2019 Jun;51(6):1252-61

Melnikow *et al*, 2016. Melnikow J, Fenton JJ, *et al.* Supplemental Screening for Breast Cancer in Women With Dense Breasts. A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Feb 16;164(4):268-78

Morris GJ, *et al.* 2007. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):876-84

Nieswandt *et al*, 1999. Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999 Mar 15;59(6):1295-300.

Panigoro S, Herowo BS, Panigoro, 2015, Panduan Penatalaksanaan Kanker Payudara. Komite Penanggulangan Kanker Nasional.

Park *et al*, 2016. Park MH, Hong JT. Roles of NF- κ B in Cancer and Inflammatory Diseases and Their Therapeutic Approaches. Cells 2016, 5, 15; doi:10.3390/cells5020015

Prabudi. manuaba, I.B.T.W., Sudarsa, I.W. 2020. Overexpression of nuclear factor kappa B (NF- κ B) protein as a risk factor for anthracyclin chemoresistance in luminal a subtype locally advanced breast cancer (LABC) at Sanglah General Hospital, Bali - Indonesia. Bali Medical Journal 9(3): 686-690. DOI: 10.15562/bmj.v9i3.2041

Purwanto, H., Handojo, D., Haryono, SJ & Harahap WA., Panduan Penatalaksanaan Kanker Payudara. PERABOI, Jakarta, 2015.

Rachidi *et al*, 2017. Rachidi S, Metelli A, Riesenber B, Wu BX, Nelson MH, Wallace C, *et al.* Platelets subvert T cell immunity against cancer via GARP-TGF β

axis. Sci Immunol. 2017 May 5;2(11):eaa17911. <https://doi.org/10.1126/sciimmunol.aai7911>

Rasmi et al., 2020. Rasmi RR, Sakthivel KM, et al. NF- κ B inhibitors in treatment and prevention of lung cancer. *Biomedicine & Pharmacotherapy*, Volume 130, 2020, 110569, ISSN 0753-3322, <https://doi.org/10.1016/j.biopha.2020.110569>.

Reddy, S.M., Sinha, A.K., Hsu, L., Barcenas, C.H. and Valero, V., 2016. Recurrence and survival outcomes of triple-negative breast cancer survivors disease-free at 5-years and relationship to low hormone receptor positivity (1-9% versus < 1%).

Revoredo *et al.*, 2020. Revoredo Camila, Pereira Renato, *et al.* Expression of Nrf2 and NF- κ B transcription factors in breast cancer and breast fibroadenoma: Insights for a new therapeutic approach, *Oncotarget*, 2020, Vol. 11, (No. 18), pp: 1629-1636

Ribatti *et al.*, 2020. Ribatti D, Tamma R, Annese T. Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. *Transl Oncol.* 2020 Jun;13(6):100773. <https://doi.org/10.1016/j.tranon.2020.100773>

Rojo *et al.*, 2016. Rojo Federico, Perez Abel, *et al.* Non-canonical NF- κ B pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma. *British Journal of Cancer* (2016) 115, 322–331 | doi: 10.1038/bjc.2016.204

Sarkar *et al.*, 2013. Sarkar D.K, Jana D, Patil P.S, *et al.* Role of NF- κ B as a Prognostic Marker in Breast Cancer : A Pilot Study in Indian Patients. *Indian J Surg Oncol* (September 2013) 4(3):242–247 DOI 10.1007/s13193-013-0234-y

Simons *et al.*, 2021. Simons JM, Jacobs JG, Roijers JP, et al. Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single centre cohort study. *Breast Cancer Res Treat.* 2021;185(2):441-451. doi:10.1007/s10549-020-05966

Singh *et al.*, 2021. Singh, D.D.; Yadav, D.K. TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. *Biomedicines* 2021, 9, 876. <https://doi.org/10.3390/biomedicines9080876>

Sobri *et al.*, 2017. Sobri FB, Azhar Y, dkk. Manajemen Terkini Kanker Payudara. 1st ed. 2017

Song *et al.*, 2022. Song Z, Chang Y, Jia H, *et al.* Metadherin inhibits triple-negative breast cancer chemosensitivity to paclitaxel via activation of the AKT/GSK-3 β signaling pathway. Research Square. <https://doi.org/10.21203/rs.3.rs-2238063/v1>

Spring *et al.*, 2020. Spring LM, Fell G, Arfe A, *et al.* Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020;26(12):2838-2848. doi:10.1158/1078-0432.CCR-19-3492

Sung *et al.*, 2020. Sung H, Ferlay J, Siegel RL, *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality for 36 Cancers in 185 Countries. CA C Cancer J Clin. 2021 May

Suyatno *et al.*, 2020. Suyatno, Rizki K.A., Andinata B, *et al.* Panduan Penatalaksanaan Kanker 2020. Jakarta: PERABOI.

Suyatno *et al.*, 2023. Suyatno, Andinata B, Wibisana IGN, dkk. Panduan Tatalaksana Kanker Payudara Peraboi 2023 Edisi III. PERABOI, Jakarta, 2023.

Tamimi *et al.*, 2012. Tamimi RM, Colditz GA, *et al.* Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012 Jan;131(1):159-67

Taylor, CR & Rudbeck, L., 2013, Immunohistochemical Staining Methods. An Agilent Technologies Company, Dako Denmark.

Thon *et al.*, 2012. Thon JN, Italiano JE. Platelets: Production, Morphology and Ultrastructure. In: Gresele P, Born GVR, Patrono C, Page CP, editors. Antiplatelet Agents [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012 [cited 2022 May 18]. p. 3–22. (Handbook of Experimental Pharmacology; vol. 210). Available from: http://link.springer.com/10.1007/978-3-642-29423-5_1 https://doi.org/10.1007/978-3-642-29423-5_1

Vaidya *et al.*, 2018. Vaidya JS, Massarut S, Vaidya HJ, et al. Rethinking neoadjuvant chemotherapy for breast cancer. *BMJ*. 2018;360:j5913. doi:10.1136/bmj.j5913

Wang *et al.*, 2011. Wang, C., & Yang, Q. (2011). Astrocyte elevated gene-1 and breast cancer. *Oncology letters*, 2(3), 399-405.

WHO, 2019. WHO classification of tumours. Breast Tumours. International Agency for Research on Cancer; 2019.

WHO, 2019. WHO classification of tumours. Breast Tumours. International Agency for Research on Cancer; 2019.

Widodo, I., Dwianingsih, E. K., Anwar, S. L., Triningsih, F. E., Utoro, T., & Aryandono, T. (2017). Prognostic value of clinicopathological factors for Indonesian breast carcinomas of different molecular subtypes. *Asian Pacific Journal of Cancer Prevention: APJCP*, 18(5), 1251.

Yang Zheng Jun, Yu Yue (2016). The prognostic value of node status in different breast cancer subtypes. *Oncotarget*, Advance Publications 2016. www.impactjournals.com/oncotarget

Yin, L., Duan, J. J., Bian, X. W., and Yu, S. C. (2020). Triple-negative Breast Cancer Molecular Subtyping and Treatment Progress. *Breast Cancer Res*. 22, 61–13. doi:10.1186/s13058-020-01296-5

Yu Hui, Lin Liangbin (2020). Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Springer Nature. *Signal Transduction and Targeted Therapy* (2020) 5:209 ; <https://doi.org/10.1038/s41392-020-00312-6>

Yulian *et al*, 2023. Yulian Erwin, Fachriza Ihza. Five-year survival of triple-negative breast cancer and the associated clinicopathological factors: a study in an Indonesian tertiary hospital. *Medical Journal of Indonesia*. pISSN: 0853-1773 • eISSN: 2252-8083 <https://doi.org/10.13181/mji.oa.247161> *Med J Indones*. 2023;32:230–7



Hubungan antara Ekspresi AEG-1 dan NF-kappa Beta/p65 Pada Triple Negative Breast Cancer Operable Dengan Disease Free Survival

Muhammad Dhanny Irawan, dr. Herjuna Hardiyanto Sp.B., Subsp. Onk (K); Prof. Dr. dr. Teguh Aryandono Sp.B., Su
Universitas Gadjah Mada, 2024 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Yun Li *et al.*, 2022. Yunli, Zhang, et al. Recent advances in therapeutic strategies for triple negative breast cancer. *Journal of Hematology & Oncology* (2022) 15:121

Zaslavsky *et al.*, 2020. Zaslavsky AB, Adams MP, Cao X, Maj T, Choi JE, Stangl-Kremser J, *et al.* Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors. *Sci Rep.* 2020 Dec;10(1):19296. <https://doi.org/10.1038/s41598-020-76351-4>